|16.58|| +0.23 / +1.41%|
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics. It operates through the Developed Markets and Emerging Markets. The Developed Markets segment offers over-the-counter and medical products as well as alliance and contract service revenues, in the areas of dermatology and podiatry, neurology, gastrointestinal disorders, eye health, oncology and urology, dentistry, aesthetics, and women's health. The Emerging Markets consists of branded generic pharmaceutical and branded pharmaceuticals; over-the-counter and medical device products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
|Joseph C. Papa||Chairman & Chief Executive Officer|
|Paul S. Herendeen||Chief Financial Officer & Executive VP-Finance|
|Tage Ramakrishna||Chief Medical Officer, President-R&D|
|Anne C. Whitaker||Executive Vice President|
|Christina M. Ackermann||Executive Vice President & General Counsel|